Trial Profile
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Plexxikon
- 04 Oct 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Mar 2010 Planned end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
- 15 Mar 2010 New source identified and integrated (ClinicalTrials.gov record NCT01090570).